ADAM10-mediated Notch signalling is also implicated in GI cancers [22,23], with roles in adenoma formation and stem cell maintenance, and antibodies targeting ADAM10 in colorectal (CRC) and GBM models inhibited tumour growth and impacted the tumour microenvironment [24,25,26,27]. Here, ADAM10 is linked to neoplasm.